본문으로 건너뛰기
← 뒤로

Long-term outcomes and prognostic factors of patients with lung metastases from differentiated thyroid cancer after radioiodine therapy in Japan.

1/5 보강
Endocrine journal 📖 저널 OA 50% 2022: 0/4 OA 2023: 0/7 OA 2024: 1/3 OA 2025: 6/6 OA 2026: 6/6 OA 2022~2026 2023 Vol.70(3) p. 315-322
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 3/4)

유사 논문
P · Population 대상 환자/모집단
62 patients with lung metastases from DTC who received RIT between March 2005 and December 2016.
I · Intervention 중재 / 시술
RIT between March 2005 and December 2016
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The 5- and 10-year OS rates of DTC patients with lung metastases were similar to those in previous Japanese reports, which included a smaller sample size compared with ours. Patients with ≤1 cm lung metastases, aged ≤55 years, and a thyroglobulin level of ≤400 ng/mL at the initial RIT had favorable outcomes.

Akatani N, Wakabayashi H, Kayano D, Inaki A, Takata A, Hiromasa T

📝 환자 설명용 한 줄

Long-term survival in patients with differentiated thyroid cancer (DTC) and lung metastasis remains unexplored in Japan.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 추적기간 7.9 years

이 논문을 인용하기

↓ .bib ↓ .ris
APA Akatani N, Wakabayashi H, et al. (2023). Long-term outcomes and prognostic factors of patients with lung metastases from differentiated thyroid cancer after radioiodine therapy in Japan.. Endocrine journal, 70(3), 315-322. https://doi.org/10.1507/endocrj.EJ22-0463
MLA Akatani N, et al.. "Long-term outcomes and prognostic factors of patients with lung metastases from differentiated thyroid cancer after radioiodine therapy in Japan.." Endocrine journal, vol. 70, no. 3, 2023, pp. 315-322.
PMID 36567077 ↗

Abstract

Long-term survival in patients with differentiated thyroid cancer (DTC) and lung metastasis remains unexplored in Japan. This study aimed to investigate the long-term survival and prognostic factors of radioiodine therapy (RIT) in a University Hospital setting. This retrospective study included 62 patients with lung metastases from DTC who received RIT between March 2005 and December 2016. According to the I whole-body scan and chest computed tomography results, lung metastases were classified as I-avid or non-I-avid, and miliary, micronodular, or macronodular metastases. The 5- and 10-year overall survival (OS) rates from the initial RIT were calculated by the Kaplan-Meier method, and a proportional hazard fit analysis was performed to determine prognostic factors. With a median follow-up of 7.9 years, the 5- and 10-year OS rates from the initial RIT were 93% and 72%, respectively. Univariable and multivariable analyses of patient subgroups revealed that macronodular lung metastases (defined as nodules >1 cm), older age at initial RIT, and high thyroglobulin values (>400 ng/mL) at initial RIT predicted low OS. The 5- and 10-year OS rates of DTC patients with lung metastases were similar to those in previous Japanese reports, which included a smaller sample size compared with ours. Patients with ≤1 cm lung metastases, aged ≤55 years, and a thyroglobulin level of ≤400 ng/mL at the initial RIT had favorable outcomes.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반